Figure 5
Figure 5. Antitumor efficacy of 131I-BC8 (anti-CD45) in a human T-NHL xenograft model. Tumor volume (A) and progression-free survival (B) in mice bearing human T-NHL xenografts (CCRF-CEM) after no treatment, BHV1 labeled with 300 μCi 131I (control), BC8 labeled with 300 μCi 131I, or BC8 labeled with 400 μCi 131I.

Antitumor efficacy of 131I-BC8 (anti-CD45) in a human T-NHL xenograft model. Tumor volume (A) and progression-free survival (B) in mice bearing human T-NHL xenografts (CCRF-CEM) after no treatment, BHV1 labeled with 300 μCi 131I (control), BC8 labeled with 300 μCi 131I, or BC8 labeled with 400 μCi 131I.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal